Puretech Health PLC (PTCHF) — SEC Filings
Puretech Health PLC (PTCHF) — 35 SEC filings. Latest: 6-K (Dec 18, 2025). Includes 28 6-K, 2 20-F, 2 SC 13G/A.
View Puretech Health PLC on SEC EDGAR
Overview
Puretech Health PLC (PTCHF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 10, 2025: PureTech Health plc announced the results of its Annual General Meeting held on June 16, 2025, via a press release on December 10, 2025. The company, listed on LSE and Nasdaq under ticker PRTC, provided an update statement regarding the meeting's outcomes.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 5 bullish, 29 neutral, 1 mixed. The dominant filing sentiment for Puretech Health PLC is neutral.
Filing Type Overview
Puretech Health PLC (PTCHF) has filed 28 6-K, 2 20-F, 1 SC 13G, 2 SC 13G/A, 2 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of PTCHF's 29 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Raju Kucherlapati, Ph.D.
- Michele Holcomb, PhD
- Bharatt Chowrira
Industry Context
PureTech Health plc operates in the pharmaceutical preparations industry, focusing on the development and commercialization of healthcare products.
Top Tags
agm (4) · sec-filing (4) · results (3) · governance (3) · press-release (3) · biotech (3) · amendment (3) · tender-offer (3) · capital-return (3) · share-repurchase (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Trial Phase | Phase 2b | Successful completion of this stage for LYT-100 |
| Initial Funding | $100M | Committed by PureTech Health plc to Seaport Therapeutics for development. |
| Reporting Period End Date | June 30, 2024 | Indicates the end of the financial period covered by the report. |
| Comparative Period End Date | June 30, 2023 | Used for comparing financial performance against the prior year. |
| Balance Sheet Date | December 31, 2022 | Date as of which detailed equity components are reported. |
| Tender Offer Size | $100M | Total amount PureTech Health plans to spend on repurchasing shares. |
| Offer Price | $25.00 | The price per share at which the tender offer will be made. |
| Filing Date | 20240530 | Indicates the date of the amendment filing. |
| Tender Offer Value | $100 million | Maximum amount PureTech Health plans to spend on repurchasing shares. |
| Offer Price per Share | $2.50 | The price at which PureTech Health is offering to buy back its shares. |
| Fiscal Year End | 2023-12-31 | Conformed period of report |
| SIC Code | 2834 | Standard Industrial Classification |
| SEC File Number | 001-39670 | SEC file number for PureTech Health plc |
| Series A Financing | $100 million | Amount raised for Seaport Therapeutics to fund rare disease drug development. |
| Proposed Capital Return | $100 million | Amount to be returned to shareholders |
Forward-Looking Statements
- {"claim":"Invesco Ltd. will continue to be a significant institutional holder of PureTech Health plc shares.","entity":"Invesco Ltd.","targetDate":"2025-02-12","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Puretech Health PLC (PTCHF)?
Puretech Health PLC has 35 recent SEC filings from Jan 2024 to Dec 2025, including 28 6-K, 2 20-F, 2 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PTCHF filings?
Across 35 filings, the sentiment breakdown is: 5 bullish, 29 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Puretech Health PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Puretech Health PLC (PTCHF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Puretech Health PLC?
Financial highlights for Puretech Health PLC are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for PTCHF?
The investment thesis for PTCHF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Puretech Health PLC?
Key executives identified across Puretech Health PLC's filings include Raju Kucherlapati, Ph.D., Michele Holcomb, PhD, Bharatt Chowrira.
What are the main risk factors for Puretech Health PLC stock?
Of PTCHF's 29 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Puretech Health PLC?
Recent forward-looking statements from Puretech Health PLC include guidance on {"claim":"Invesco Ltd. will continue to be a significant institutional holder of PureTech Health plc shares.","entity":".